THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
The other half received the same aggressive cholesterol-lowering treatment, but their injections contained Repatha. After 48 weeks, their LDL cholesterol had dropped to unprecedented low levels (the ...
The FOURIER-OLE studies are the longest trials with a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) to date, with patients receiving Repatha for a median of 5 years and some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback